Esophageal cancer—the five year survivors
- 22 December 2010
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (2), 179-183
- https://doi.org/10.1002/jso.21784
Abstract
Background Esophageal cancer in the United States carries a poor prognosis with overall 5 year survival rate of approximately 10%. Due to this dismal outcome, data analyzing factors predictive of survival for greater than 5 years are not available. Methods Single institution retrospective review of esophageal resection for curative intent from 1984 to 2004. We identified 50 actual 5 year survivors (long term survivors, LTS) out of 266 patients (19%) with invasive esophageal cancer and, using multivariate logistic regression, compared characteristics between the LTS, and short-term (P = 0.81) or in the utilization of neoadjuvant therapy in the LTS versus STS (58% vs. 62%, respectively, P = 0.36). The LTS group was significantly more likely to have pathologic complete response (69% vs. 41%, P < 0.001), lower pathologic T stage, i.e., pT0, pTis, or pT1 (83% vs. 45%, P < 0.001), pN0 stage (97% vs. 68%, P < 0.001), favorable tumor differentiation (well or well to moderate, 39% vs. 13%, P < 0.001), and absence of angiolymphatic (88% vs. 69%, P < 0.01) or perineural invasion (95% vs. 83%, P = 0.04). In comparing the factors predictive of outcome in LTS versus the STS with increasing relative risk, absence of perineural invasion (RR 0.41 (0.27, 0.61)), negative margins (RR 0.41 (0.29, 0.57)), absence of angiolymphatic invasion (RR 0.39 (0.30, 0.51)), pN0 stage (RR 1.37 (1.23, 1.52)), pT0 or pT1 (RR 1.85 (1.64, 2.07)), pathologic complete response (RR 2.02 (1.76, 2.31)), and favorable tumor grade (RR 3.00 (2.49, 3.61)) were associated with improved survival. Conclusion Tumor biological factors including favorable tumor grade may be the most important influence on 5 year actual survival in esophageal cancer. J. Surg. Oncol. 2011; 103:179–183.Keywords
This publication has 24 references indexed in Scilit:
- Recurrence after Esophagectomy for Adenocarcinoma: Defining Optimal Follow-Up Intervals and TestingJournal of the American College of Surgeons, 2010
- Long‐term survivors of esophageal cancer: Disease‐specific quality of life, general health and complicationsJournal of Surgical Oncology, 2009
- Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced SurvivalThe Annals of Thoracic Surgery, 2009
- Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinomaWorld Journal of Gastroenterology, 2009
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781Journal of Clinical Oncology, 2008
- Modern 5-Year Survival of Resectable Esophageal Adenocarcinoma: Single Institution Experience with 263 PatientsJournal of the American College of Surgeons, 2006
- Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancerDiseases of the Esophagus, 2006
- Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysisSurgery, 2005
- The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinomaJournal of the American College of Surgeons, 2004
- Minimally Invasive EsophagectomyAnnals of Surgery, 2003